-
Part 1 | Session 10 Plenary session 6 – Diuretics: old drugs, new data, new approaches
-
Part 2 | Session 5 Plenary session 9 – Managing “metals”
-
Part 2 | Session 7 Plenary session 10 – Management of diabetes with kidney disease
-
Part 2 | Session 8 Plenary session 11 – Managing frail and elderly patients
-
Part 2 | Session 9 Plenary session 12 – Managing end-stage disease: focus on QoL
-
Part 1 | Session 1 Plenary session 1 – HFpEF
-
Part 1 | Session 3 Plenary session 2 – SGLT2 updates
-
Part 1 | Session 5 Plenary session 3 – Weight management in CRM disease
-
Part 1 | Session 7 Plenary session 4 – Guidelines implementation for acutely ill patients
-
Part 1 | Session 8 Plenary session 5 – Mineralocorticoids antagonists in CRM disease
e-SPACE Cardio-Renal-Metabolic 2023 was the third edition of the annual global online conference that explores how leading experts, in cardiology, nephrology, and diabetology, are treating the interrelated diseases.
Course leadership Prof Stefan Anker (Berlin, DE), Dr Javed Butler (Texas, US), Prof Antonio Ceriello (Milan, IT), Prof Tara I Chang (California, US), Prof Ian de Boer (Washington, US), Prof Peter Rossing (Copenhagen, DK) and Prof Shelley Zieroth (Winnipeg, CA) lead an interactive programme of plenary sessions, meet the expert, case discussions and satellite symposium sessions focusing on the patient journey.
For the first time, e-SPACE Cardio-Renal-Metabolic 2023 brought together TMA’s mandate for the delivery of continuing professional development to healthcare professionals to achieve concordance with appropriate treatment plans, alongside KDIGO's mission to improve the care and outcomes of patients with kidney disease worldwide through the development and implementation of global clinical practice guidelines, with Radcliffe Cardiology’s goal to deliver cardiovascular knowledge to best support cardiovascular communities transform theory into practice.
Learning Objectives
- Review the burden of diabetes, kidney disease and heart failure including morbidity, excess mortality, and reduced quality of life affecting individuals around the world
- Describe the complexity and interlink between the three conditions
- Discuss existing guidelines and best approaches for screening patients
- Review evidence-based management strategies for diabetes, cardiovascular disease, heart failure, kidney disease & obesity including SLGT2i, GLP-1RA, new non-steroidal mineralocorticoid receptor antagonists and other emerging therapies
- Foster cross-collaboration between other cardiorenal / metabolic specialists and primary care physicians and allied health care professionals in order to improve patients outcomes
Target Audience
- Cardiologists
- Nephrologists
- Diabetologists
- General Practitioners (GPs)
- HF Specialists
- Nurses, Pharmacists, and other Allied Healthcare Professionals
More from this programme
Part 1
Day One
Part 2
Day Two
Faculty Biographies
Stefan Anker
Professor of Cardiology
Prof Stefan D Anker is a German cardiologist born in Berlin, Germany. He studied medicine at Charité Medical School of Humboldt University Berlin, where he completed his medical degree in 1993. He later pursued research training at the National Heart & Lung Institute, Imperial College London, completing his PhD in 1998. Following his return to Germany, Prof Anker held academic and research positions at Charité Berlin and later at University Medical Center Göttingen before returning to Charité in 2017 to serve as Professor of (Tissue) Homeostasis in Cardiology & Metabolism. His work has taken him across multiple institutions and countries through long-standing international collaborations.
Academic History
Prof Anker began his medical education at Charité Medical School, graduating in 1993. He then continued postgraduate academic training in both Germany and the United Kingdom, completing his PhD at the National Heart & Lung Institute in London…
Muthiah Vaduganathan
Co-Director, Center for Cardiometabolic Implementation Science
Dr. Muthiah Vaduganathan is a cardiologist and clinical trialist based in Boston, Massachusetts, United States. He practices at Brigham and Women’s Hospital and holds an academic appointment at Harvard Medical School. Dr. Vaduganathan is internationally recognised for his work at the intersection of cardiovascular, kidney, and metabolic disease, with a particular focus on translating evidence from large-scale clinical trials into routine clinical practice.
Academic History
Dr. Vaduganathan completed his medical training in the United States and pursued advanced postgraduate training in cardiovascular medicine, with a focus on heart failure and preventive cardiology. His academic development has been closely aligned with outcomes research, trial methodology, and translational science, positioning him as a leading investigator in cardio-kidney-metabolic therapeutics.
Career Overview
Dr. Vaduganathan is a Cardiologist and Clinical…
Comments